Equecabtagene autoleucel vs HRC0202
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Equecabtagene autoleucel
Marketed by IASO Biotherapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT06464991 (registry estimate)
No aligned efficacy figure on record for this race.
HRC0202
Developed by Hrain Biotechnology Co., Ltd.
NCT04003168 · Phase 1 · status unknown
This is a small, single-arm, open-label safety study with no control group, so it cannot show whether the therapy works better than an alternative. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The published report covers seven treated patients, fewer than the study's listed enrollment.
Reported efficacy
Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0 (28 days post infusion): In seven patients with relapsed/refractory multiple myeloma previously treated with anti-BCMA CAR-T (four relapsed, three refractory), the best overall response rate was 71.4% (5/7), with stringent complete response or complete response achieved in three patients. Cytokine release syndrome of grades 1-2 occurred in three patients (42.9%) and grade >=3 in two patients (28.6%).
Result source: NCT04003168
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Equecabtagene autoleucel | HRC0202 |
|---|---|---|
| PFS, median | —Trial running · NCT06464991 | —Not reported |
| OS, median | —Trial running · NCT06464991 | —Not reported |
| ORR | —Trial running · NCT06464991 | —Not reported |
| VGPR or better | —Trial running · NCT06464991 | —Not reported |
| MRD negativity | —Trial running · NCT06464991 | —Not reported |
PFS, median
- Equecabtagene autoleucel
- —Trial running · NCT06464991
- HRC0202
- —Not reported
OS, median
- Equecabtagene autoleucel
- —Trial running · NCT06464991
- HRC0202
- —Not reported
ORR
- Equecabtagene autoleucel
- —Trial running · NCT06464991
- HRC0202
- —Not reported
VGPR or better
- Equecabtagene autoleucel
- —Trial running · NCT06464991
- HRC0202
- —Not reported
MRD negativity
- Equecabtagene autoleucel
- —Trial running · NCT06464991
- HRC0202
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Equecabtagene autoleucel: no structured comparison results are available for Multiple Myeloma.
HRC0202: no structured comparison results are available for Multiple Myeloma.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Equecabtagene autoleucel's landscape · HRC0202's landscape